\
&
Contact us
\
&
Contact us
About the programme
The aim of the European Chips Act, is to bolster Europe’s competitiveness and resilience in semiconductor technologies and applications to support the green and digital transition. The Chips for Europe Initiative, part of the EU Chips Act, aims to reinforce the European semiconductor ecosystem and Europe’s technological leadership and will be implemented by the Chips Joint Undertaking (Chips JU).
The Chips JU, with funding from both Digital Europe and Horizon Europe, will
The Chips JU is a public-private partnership that supports research, development, and manufacturing capacities in the European semiconductor ecosystem.
marie.timmermann@fwo.be
+32 2 550 15 59
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
